Sage Journals: Discover world-class research

Abstract

Background:

Despite sensitivity of MRI to diagnose multiple sclerosis (MS), prognostic biomarkers are still needed for optimized treatment.

Objective:

The objective of this paper is to identify cerebrospinal fluid (CSF) diagnostic biomarkers of MS using quantitative proteomics and to analyze their expression at different disease stages.

Methods:

We conducted differential analysis of the CSF proteome from control and relapsing–remitting MS (RRMS) patients followed by verification by ELISA of candidate biomarkers in CSF and serum in control, clinically isolated syndrome (CIS), RRMS and progressive MS (PMS) patients.

Results:

Twenty-two of the 527 quantified proteins exhibited different abundances in control and RRMS CSF. These include chitinase 3-like protein 1 (CHI3L1) and 2 (CHI3L2), which showed a strong expression in brain of MS patients, especially in astrocytes and microglial cells from white matter plaques. CSF and serum CHI3L1 levels increased with the disease stage and CIS patients with high CSF (>189 ng/ml) and serum (>33 ng/ml) CHI3L1 converted more rapidly to RRMS (log rank test, p < 0.05 and p < 0.001, respectively). In contrast, CSF CHI3L2 levels were lower in PMS than in RRMS patients. Accordingly, CSF CHI3L1/CHI3L2 ratio accurately discriminated PMS from RRMS.

Conclusions:

CSF CHI3L1 and CHI3L2 and serum CHI3L1 might help to define MS disease stage and have a prognostic value in CIS.

Keywords

Multiple sclerosis biomarkers proteomics cerebrospinal fluid diagnosis prognosis

Get full access to this article

View all access options for this article.

References

Polman

Reingold

Banwell

. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292–302.

Korteweg

Tintoré

Uitdehaag

. MRI criteria for dissemination in space in patients with clinically isolated syndromes: A multicentre follow-up study. Lancet Neurol 2006; 5: 221–227.

Graber

Dhib-Jalbut

. Biomarkers of disease activity in multiple sclerosis. J Neurol Sci 2011; 305: 1–10.

Brettschneider

Petzold

Junker

. Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis. Mult Scler 2006; 12: 143–148.

Kuhle

Leppert

Petzold

. Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology 2011; 76: 1206–1213.

Dagley

Emili

Purcell

. Application of quantitative proteomics technologies to the biomarker discovery pipeline for multiple sclerosis. Proteomics Clin Appl 2013; 7: 91–108.

Chiasserini

Di Filippo

Candeliere

. CSF proteome analysis in multiple sclerosis patients by two-dimensional electrophoresis. Eur J Neurol 2008; 15: 998–1001.

Hammack

Fung

Hunsucker

. Proteomic analysis of multiple sclerosis cerebrospinal fluid. Mult Scler 2004; 10: 245–260.

Kroksveen

Guldbrandsen

Vedeler

. Cerebrospinal fluid proteome comparison between multiple sclerosis patients and controls. Acta Neurol Scand Suppl 2012: 90–96.

10.

Lehmensiek

Sussmuth

Tauscher

. Cerebrospinal fluid proteome profile in multiple sclerosis. Mult Scler 2007; 13: 840–849.

11.

Noben

Dumont

Kwasnikowska

. Lumbar cerebrospinal fluid proteome in multiple sclerosis: Characterization by ultrafiltration, liquid chromatography, and mass spectrometry. J Proteome Res 2006; 5: 1647–1657.

12.

Ottervald

Franzen

Nilsson

. Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers. J Proteomics 2010; 73: 1117–1132.

13.

Stoop

Dekker

Titulaer

. Multiple sclerosis-related proteins identified in cerebrospinal fluid by advanced mass spectrometry. Proteomics 2008; 8: 1576–1585.

14.

Stoop

Dekker

Titulaer

. Quantitative matrix-assisted laser desorption ionization-Fourier transform ion cyclotron resonance (MALDI-FT-ICR) peptide profiling and identification of multiple-sclerosis-related proteins. J Proteome Res 2009; 8: 1404–1414.

15.

Stoop

Singh

Dekker

. Proteomics comparison of cerebrospinal fluid of relapsing remitting and primary progressive multiple sclerosis. PLoS One 2010; 5: e12442.

16.

Tumani

Lehmensiek

Rau

. CSF proteome analysis in clinically isolated syndrome (CIS): Candidate markers for conversion to definite multiple sclerosis. Neurosci Lett 2009; 452: 214–217.

17.

Comabella

Fernández

Martin

. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain 2010; 133: 1082–1093.

18.

Rigau

Mania

Befort

. Lethal multiple sclerosis relapse after natalizumab withdrawal. Neurology 2012; 79: 2214–2216.

19.

R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2011.

20.

Polman

Reingold

Edan

. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 2005; 58: 840–846.

21.

Lucchinetti

Bruck

Parisi

. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707–717.

22.

Johansen

Milman

Hansen

. Increased serum YKL-40 in patients with pulmonary sarcoidosis—a potential marker of disease activity? Respir Med 2005; 99: 396–402.

23.

Johansen

Stoltenberg

Hansen

. Serum YKL-40 concentrations in patients with rheumatoid arthritis: Relation to disease activity. Rheumatology (Oxford) 1999; 38: 618–626.

24.

Koutroubakis

Petinaki

Dimoulios

. Increased serum levels of YKL-40 in patients with inflammatory bowel disease. Int J Colorectal Dis 2003; 18: 254–259.

25.

Lee

Da Silva

Dela Cruz

. Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. Annu Rev Physiol 2011; 73: 479–501.

26.

Nordenbaek

Johansen

Halberg

. High serum levels of YKL-40 in patients with systemic sclerosis are associated with pulmonary involvement. Scand J Rheumatol 2005; 34: 293–297.

27.

Bonneh-Barkay

Bissel

Kofler

. Astrocyte and macrophage regulation of YKL-40 expression and cellular response in neuroinflammation. Brain Pathol 2012; 22: 530–546.

28.

Bonneh-Barkay

Wang

Starkey

. In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases. J Neuroinflammation 2010; 7: 34.

29.

Bonneh-Barkay

Bissel

Wang

. YKL-40, a marker of simian immunodeficiency virus encephalitis, modulates the biological activity of basic fibroblast growth factor. Am J Pathol 2008; 173: 130–143.

30.

Lafon-Cazal

Adjali

Galeotti

. Proteomic analysis of astrocytic secretion in the mouse. Comparison with the cerebrospinal fluid proteome. J Biol Chem 2003; 278: 24438–24448.

31.

Stoop

Singh

Stingl

. Effects of natalizumab treatment on the cerebrospinal fluid proteome of multiple sclerosis patients. J Proteome Res 2013; 12: 1101–1107.

32.

Prakash

Bodas

Prakash

. Diverse pathological implications of YKL-40: Answers may lie in ‘outside-in’ signaling. Cell Signal 2013; 25: 1567–1573.

33.

Cantó

Reverter

Morcillo-Suárez

. Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis. Mult Scler 2012; 18: 983–990.

34.

Reiber

. Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta 2001; 310: 173–186.

35.

Tsuruha

Masuko-Hongo

Kato

. Autoimmunity against YKL-39, a human cartilage derived protein, in patients with osteoarthritis. J Rheumatol 2002; 29: 1459–1466.

36.

Sekine

Masuko-Hongo

Matsui

. Recognition of YKL-39, a human cartilage related protein, as a target antigen in patients with rheumatoid arthritis. Ann Rheum Dis 2001; 60: 49–54.

37.

Trinh

Figueira

. Isolation and sequence of a novel human chondrocyte protein related to mammalian members of the chitinase protein family. J Biol Chem 1996; 271: 19415–19420.

38.

Areshkov

Avdieiev

Balynska

. Two closely related human members of chitinase-like family, CHI3L1 and CHI3L2, activate ERK1/2 in 293 and U373 cells but have the different influence on cell proliferation. Int J Biol Sci 2012; 8: 39–48.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.79 MB

Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis

Abstract

Background:

Objective:

Methods:

Results:

Conclusions:

Keywords

Get full access to this article

References

Supplementary Material